NeuroPace (NPCE) Amortization of Deferred Charges (2020 - 2026)
NeuroPace's (NPCE) quarterly Amortization of Deferred Charges came in at $68000.0 in Q1 2026, up 38.78% year-on-year from $49000.0 in Q1 2025, and up 106.6% quarter-over-quarter from -$1.0 million in Q4 2025.
NeuroPace (NPCE) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
NeuroPace's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $68000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 38.78% year-over-year to $68000.0 in Q1 2026; TTM through Mar 2026 was -$863000.0, a 232.36% decrease from a year earlier, with the FY2025 full-year figure at $237000.0, down 84.83% from the prior year.
- Amortization of Deferred Charges advanced to $68000.0 in Q1 2026 per NPCE's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $403000.0 in Q4 2024 and bottomed at -$1.8 million in Q4 2022.
- The 5-year median for Amortization of Deferred Charges is $100000.0 (2022), against an average of -$44187.5.
- Across the five-year window, Amortization of Deferred Charges slumped 782.0% in 2022 and jumped 430.26% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at -$1.8 million in 2022, then jumped by 104.31% to $76000.0 in 2023, then soared by 430.26% to $403000.0 in 2024, then tumbled by 355.83% to -$1.0 million in 2025, then jumped by 106.6% to $68000.0 in 2026.
- Per Business Quant, the three latest NPCE Amortization of Deferred Charges figures stand at $68000.0 (Q1 2026), -$1.0 million (Q4 2025), and $100000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | -1.03 Mn |
| Dec 31, 2025 | -1.03 Mn |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 403,000.00 |
| Dec 31, 2024 | 403,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 378,000.00 |
| Mar 31, 2024 | 378,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |